Diabetic Macular Edema – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key diabetic macular edema patient populations, covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download.
Use the Extrapolated Worldwide Coverage dashboard to do the following:
- View 10-year forecasts of the total prevalent cases for all 171 countries, stratified by region and World Bank income status.
- Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
- Visualize global correlations between disease risk or size of patient population and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
- Generate and export global heat maps of disease risk or size of patient population.
The Extrapolated Worldwide Coverage dashboard is available as an Excel file in the Downloads section at the top right of this page. It is available for purchase by clients with subscriptions to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact Clarivate.support@clarivate.com.
Related Market Assessment Reports
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Uveitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Noninfectious Uveitis–Posterior Segment
Most vision loss from uveitis stems from persistent inflammation in the posterior segment of the eye. While noninfectious anterior uveitis is usually managed effectively with topical steroids,…
Report
Dry and Wet Age-Related Macular Degeneration – Current Treatment – Treatment Algorithms: Claims Data Analysis – Wet Age-Related Macular Degeneration (US)
The U.S. market for wet age-related macular degeneration (wet AMD) is in transition as newer therapies, including biosimilars, increasingly enter the treatment algorithm. While intravitreal options…
